Inhibition of histone deacetylases by Trichostatin A leads to a HoxB4-independent increase of hematopoietic progenitor/stem cell frequencies as a result of selective survival

References

• Zardo G, Cimino G, Nervi C. Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia. 2008;22:1503–18.
   Google Scholar
• Bonifer C, Hoogenkamp M, Krysinska H, Tagoh H. How transcription factors program chromatin: lessons from studies of the regulation of myeloid-specific genes. Semin Immunol. 2008; 20:257–63.
   PubMedGoogle Scholar
• Kondo T. Epigenetic alchemy for cell fate conversion. Curr Opin Genet Dev. 2006;16:502–7.
   PubMedGoogle Scholar
• Clayton AL, Hazzalin CA, Mahadevan LC. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell. 2006;23:289–96.
   PubMed Web of Science ®Google Scholar
• Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol. 2002;80:363–78.
   PubMed Web of Science ®Google Scholar
• Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev. 2004;18:2315–35.
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415–28.
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, . Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–78.
   PubMed Web of Science ®Google Scholar
• Linggi BE, Brandt SJ, Sun ZW, Hiebert SW. Translating the histone code into leukemia. J Cell Biochem. 2005;96:938–50.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84.
   PubMed Web of Science ®Google Scholar
• Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1997;1:300–8.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174–9.
   PubMed Web of Science ®Google Scholar
• Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem. 2001;8:1505–11.
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1:287–99.
   PubMed Web of Science ®Google Scholar
• Milhem M, Mahmud N, Lavelle D, Araki H, Desimone J, Saunthararajah Y, . Hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood. 2004. Jun 1;103(11):4102–10. Epub 2004 Feb 19.
   PubMed Web of Science ®Google Scholar
• Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, . Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol. 2006;34:140–9.
   PubMedGoogle Scholar
• Araki H, Yoshinaga K, Boccuni P, Zhao Y, Hoffman R, Mahmud N. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. Blood. 2007;109:3570–8.
   PubMed Web of Science ®Google Scholar
• Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, . Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005;65:2537–41.
   PubMed Web of Science ®Google Scholar
• De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, . Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005;65:1505–13.
   PubMed Web of Science ®Google Scholar
• Abramovich C, Pineault N, Ohta H, Humphries RK. Hox genes: from leukemia to hematopoietic stem cell expansion. Ann NY Acad Sci. 2005;1044:109–16.
   PubMed Web of Science ®Google Scholar
• Schmittwolf C, Porsch M, Greiner A, Avots A, Müller AM. HOXB4 confers a constant rate of in vitro proliferation to transduced bone marrow cells. Oncogene. 2005;24:561–72.
   PubMedGoogle Scholar
• Schmittwolf C, Kirchhof N, Jauch A, Durr M, Harder F, Zenke M, . In vivo haematopoietic activity is induced in neurosphere cells by chromatin-modifying agents. EMBO J. 2005;24:554–66.
   PubMedGoogle Scholar
• Ruau D, Ensenat-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C, . Pluripotency-associated genes are induced by chromatin-modifying agents in neurosphere cells. Stem Cells. 2008 Apr;26(4):920–6. Epub 2008 Jan 17.
   PubMedGoogle Scholar
• Brun AC, Bjornsson JM, Magnusson M, Larsson N, Leveen P, Ehinger M, . Hoxb4-deficient mice undergo normal hematopoietic development but exhibit a mild proliferation defect in hematopoietic stem cells. Blood. 2004;103:4126–33.
   PubMed Web of Science ®Google Scholar
• Obier N, Müller, A.M. Chromatin flow cytometry identifies changes in epigenetic cell states. Cells Tissues Organs. 2009 Sep 18; [Epub ahead of print] (DOI: 10.1159/000240247)
   PubMedGoogle Scholar
• Ikuta K, Weissman IL. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci USA. 1992;89:1502–6.
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1:661–73.
   PubMed Web of Science ®Google Scholar
• Sauvageau G, Thorsteinsdottir U, Eaves CJ, Lawrence HJ, Largman C, Lansdorp PM, . Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Devel. 1995;9:1753–65.
   PubMed Web of Science ®Google Scholar
• Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell. 2002;109:39–45.
   PubMed Web of Science ®Google Scholar
• Attema JL, Papathanasiou P, Forsberg EC, Xu J, Smale ST, Weissman IL. Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc Natl Acad Sci. USA. 2007 Jul 24;104(30):12371–6. Epub 2007 Jul 18.
   PubMedGoogle Scholar
• Maltepe E, Krampitz GW, Okazaki KM, Red-Horse K, Mak W, Simon MC, . Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta. Development. 2005:3393–403.
   PubMedGoogle Scholar
• Woo HJ, Lee SJ, Choi BT, Park YM, Choi YH. Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol. 2007;82:77–84.
   PubMedGoogle Scholar
• Balasubramaniyan V, Boddeke E, Bakels R, Kust B, Kooistra S, Veneman A, . Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience. 2006;143:939–51.
   PubMed Web of Science ®Google Scholar
• Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, . Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica. 2007;92:542–5.
   PubMed Web of Science ®Google Scholar
• Devine SM, Lazarus H, Emerson SG. Clinical application of hematopoietic progenitor cell expansion: current status and future prospects. Bone Marrow Transplant. 2003;31:241–52.
   PubMedGoogle Scholar
• Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells. Nat Rev Immunol. 2004;4:878–88.
   PubMed Web of Science ®Google Scholar
• McNiece I. Ex vivo expansion of hematopoietic cells. Exp Hematol. 2004;32:409–10.
   PubMedGoogle Scholar
• Schiedlmeier B, Santos AC, Ribeiro A, Moncaut N, Lesinski D, Auer H, . HOXB4's road map to stem cell expansion. Proc Natl Acad Sci USA. 2007;104:16952–7.
   PubMedGoogle Scholar